AstraZeneca (AZN): PT Rises To $36 After Bullish Survey - Leerink

January 18, 2018 7:59 AM EST
Get Alerts AZN Hot Sheet
Price: $49.23 -0.38%

Rating Summary:
    17 Buy, 7 Hold, 4 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 9 | New: 42
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Leerink Partners analyst, Seamus Fernandez, reiterated his Market Perform rating on shares of AstraZeneca (NYSE: AZN) and raised his price target to $36 from $33 after conducting a survey of 51 oncologists which highlighted a major market opportunity for Imfinzi (durvalumab; anti-PD-L1) in
Stage III non-small cell lung cancer (NSCLC).

The analyst stated "we are raising our peak WW sales estimates for the agent by $1.5B (from $2.3B to $3.8B in 2026)". "We continue to see opportunity for reductions in OpEx as potential upside drivers, but so far see no evidence that mgmt. plans to shift toward a specialty-focused portfolio focused on delivering sustained R&D productivity with near-term earnings leverage".

For an analyst ratings summary and ratings history on AstraZeneca click here. For more ratings news on AstraZeneca click here.

Shares of AstraZeneca closed at $35.08 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Earnings